Seeking Alpha

Barron's sees the biotech sector enjoying its strongest start to a new year in a decade,...

Barron's sees the biotech sector enjoying its strongest start to a new year in a decade, and this outperformance should continue for several reasons including P/E multiples and increasing M&A. The piece also discusses product ramp-ups at InterMune (ITMN), Human Genome Sciences (HGSI) and Regneron (REGN). (submitted by Bret Jensen)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)